Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Tenofovir Alafenamide in Severe Hepatic Impairment
NCT02296853Phase 1Completed
- Sponsor
- Gilead Sciences
- Start
- Dec 2014
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of tenofovir alafenamide in hepatitis B (HBV) (2 arms), sponsored by Gilead Sciences. Primary endpoints: Area Under the Concentration-Time Curve From Time Zero to Infinity, Maximum Observed Plasma Concentration and 1 more. Started Dec 2014; status: completed.
02
Drugs
tenofovir alafenamide
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT02296853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02296853.